Neurosciences encompasses a broad range of research from the molecular (e.g. aptamer research) to clinical (e.g. research into concussion from sports).
Our goal is to be internationally recognized in 3 areas (neuro-oncology, dementia and neurodegeneration and molecular psychiatry). We have a bench to bedside approach capitalizing on our quite unique staff profile ranging from basic biomedical scientists through pharmaceutics to clinicians.
We also focus on collaborations with our local charities and a network of researchers and clinicians across the world.
We have a significant local impact in our neuro-oncology research. One strand of our Molecular Psychiatry group is research into legal highs and this research has had an impact on the government drug policy. Our Dementia and Neurodegeneration group is funded by the company.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
9
Dec 2025
Adults with autism spectrum disorder (ASD) and other neurodevelopmental disorders (NDDs) often lose access to specialized care once they age out of pediatric services.
9
Dec 2025
Blinking is a human reflex most often performed without thinking, like breathing. Although research on blinking is usually related to vision, a new Concordia study examines how blinking is connected to cognitive function such as filtering out background noise to focus on what someone is trying to say to us in a crowded room.
9
Dec 2025
Southwest Research Institute (SwRI) and Trinity University are developing an intranasal (IN) drug-device combination to treat post-traumatic stress disorder (PTSD).
9
Dec 2025
This study shows that vacancy-engineered MoS₂ nanoflowers drive mitochondrial biogenesis in human mesenchymal stem cells by activating SIRT1–PGC-1α signaling and reducing oxidative stress. These treated cells transfer more functional mitochondria to injured recipient cells, restoring energy metabolism and redox balance in multiple in vitro models.